Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
By A. Kadish, A. Dyer, J. Daubert, R. Quigg, K. Anderson, H. Calkins, D. Hoch, J. Goldberger, A. Shalaby, W. Sanders and 2 more. New England Journal of Medicine, 2004
1,832 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/91d374ed4718c5e4934344306e4894eec18f37c4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- J. Cleland
- Gerasimos Filippatos
- L. Tavazzi
- Bernard R. Chaitman
- Jeroen J. Bax
- Helmut Baumgartner
- Rick A. Nishimura
- J. Halperin
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. (2008, methodology): “Two studies have evaluated the time dependence of risk for sudden death relative to the time of diagnosis of nonischemic DCM (369,381).”
- ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, result): “06), but the findings are comparable to those of other similar trials.(647,648) The SCD-HeFT compared amiodarone, ICD, and best medical therapy in 2521 patients with CHD or nonischemic cardiomyopathy who were in NYHA functional class II or III HF with EF less than 35%.”
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005, background): “ICD implantation is reasonable in selected patients with LVEF , 30–35%, not within 40 days of a myocardial infarction, on optimal background therapy including ACE-inhibitor, ARB, beta-blocker, and an aldosterone antagonist, where appropriate, to reduce sudden death (Class of recommendation I, level ”